Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM59ZDN)

• Drug Name: Nesvacumab Drug Info
• Synonyms: REGN910; SAR307746

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DM59ZDN

Molecule-Related Drug Atlas

Drug(s) Targeting Angiopoietin-2 (ANGPT2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Faricimab	DM83SEB	Diabetic macular edema	9B71.02	Approved	[3]
AMG 386	DMQJXL4	Breast cancer	2C60-2C65	Phase 3	[4]
Trebananib	DMOG2X1	Ovarian cancer	2C73	Phase 3	[5]
RG7221	DM8J9DC	Colorectal cancer	2B91.Z	Phase 2	[6]
RO5520985	DMD3WNP	Colorectal cancer	2B91.Z	Phase 2	[7]
LY3127804	DMAC457	Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2 Trial	[8]
REGN910-3	DMTBRPO	Neovascular age-related macular degeneration	9B78.3Z	Phase 2	[9]
CVX-060	DM03LWZ	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[10]
BI 836880	DMRI6YT	Neoplasm	2A00-2F9Z	Phase 1	[11]
CVX-241	DMV74JC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Angiopoietin-2 (ANGPT2)	TTKLQTJ	ANGP2_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT01271972) Study of Nesvacumab (REGN910/ SAR307746). U.S. National Institutes of Health.
• [2] Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease. Expert Opin Investig Drugs. 2019 Oct;28(10):861-869.
• [3] Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
• [4] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [5] Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2017 Oct 15;23(20):6062-6069.
• [6] Company report (Roche pipeline: July 27, 2017)
• [7] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] ClinicalTrials.gov (NCT02713204) Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX). U.S. National Institutes of Health.
• [10] Clinical pipeline report, company report or official report of CovX (2011).
• [11] Clinical pipeline report, company report or official report of Boehringer Ingelheim.
• [12] Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A. 2010 December 28; 107(52): 22611-22616.